Carlos Martinez Rivera, MD
Endocrinology, Diabetes & Metabolism · Mayaguez, PRNPI 1356330310
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,020 of the $8,835 with a category attached, or 79.5%. Johnson & Johnson accounts for 86.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $7,388 and has fallen 97.0% since, to $220 in 2025.
Across 75 payments — averaging $117.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$8K
- Sanofi-aventis U.S. LLC$406
- AbbVie$237
- Boehringer Ingelheim$193
- Abbott$154
- AstraZeneca$63
- plus $128 from 4 others
What the payments were for
- Consulting fees$3754%
- Speaking & faculty fees$7,02079%
- Travel & lodging$741%
- Food & beverage$1,36015%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 15 | $7,655 |
| Sanofi-aventis U.S. LLC | 23 | $406 |
| AbbVie | 9 | $237 |
| Boehringer Ingelheim | 10 | $193 |
| Abbott | 7 | $154 |
| AstraZeneca | 4 | $63 |
| Dexcom, Inc. | 2 | $43 |
| Novo Nordisk | 2 | $34 |
| Eli Lilly Export S.A. Puerto Rico Branch | 2 | $32 |
| Boston Scientific | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$7,395
How this compares
$8,835 in reported general payments places this provider in the 75th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
See all endocrinology, diabetes & metabolism providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 1,548 | $1,104,303 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 1,506 | $810,554 |
| TrulicityDulaglutide | 630 | $636,634 |
| Humalog Kwikpen U-100Insulin Lispro | 1,783 | $437,259 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 460 | $432,896 |
| JardianceEmpagliflozin | 617 | $431,722 |
| SynthroidLevothyroxine Sodium | 5,342 | $405,924 |
| Xigduo XrDapaglifloz Propaned/Metformin | 345 | $244,766 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 187 | $182,252 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 91 | $153,832 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 207 | $151,437 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 12 | $108,608 |
| TradjentaLinagliptin | 174 | $104,594 |
| Humulin R U-500Insulin Regular, Human | 50 | $97,319 |
| HumalogInsulin Lispro | 459 | $67,363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $63 | $1,104,3031,548 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Glyxambi, Synjardy | $193 | $738,3091,061 claims |
| AbbVieSynthroid | $237 | $405,9245,342 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $406 | $219,231592 claims |
| Novo NordiskOzempic | $34 | $25,28324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.
Other endocrinology, diabetes & metabolism in Mayaguez
- Rose Roman TorresMayaguez$7K
- Jose Garcia MateoPonce$945K
- Manuel Alegre-HernandezSan Juan$156K
- Monica Ortiz-RiveraSan Juan$148K
- Alex Gonzalez BossoloSan Juan$110K
- Michelle Mangual GarciaSan Juan$87K
- Meliza Martinez RodriguezSan Juan$80K
- Milliette Alvarado SantiagoRio Piedras$75K
- Altagracia Alcantara GonzalezBayamon$58K
- Jean Pujals KuryBayamon$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.